Article
The importance of molecular profiling in predicting response to epidermal growth factor receptor family inhibitors in non-small-cell lung cancer: focus on clinical trial results.
Clinical lung cancer - 1 Jul 2013
Tsao Anne S, Papadimitrakopoulou Vassiliki
Abstract excerpt
In recent years, the epidermal growth factor receptor (EGFR) family has become a key focus of non-small-cell lung cancer biology and targeted therapies, such as the reversible EGFR tyrosine kinase inhibitors erlotinib and gefitinib. Initially, response to these agents was associated with certain...
Topics
- Carcinoma, Non-Small-Cell Lung
- Clinical Trials as Topic
- ErbB Receptors
- Gene Expression Profiling
- Humans
- Lung Neoplasms
- Mutation
- Protein Kinase Inhibitors
- Signal Transduction
- Survival Rate